Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
December 20, 2024
Lead Product(s) : Capsaicin
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Grunenthal
Deal Size : Inapplicable
Deal Type : Inapplicable
Grünenthal Completes Recruitment for QUTENZA® Post-Surgical Neuropathic Pain Trial
Details : Qutenza (capsaicin) topical patch is approved for neuropathic pain associated with postherpetic neuralgia and diabetic peripheral neuropathy, being investigated for post-surgical neuropathic pain.
Product Name : Qutenza
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
July 11, 2024
Lead Product(s) : Capsaicin
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Grunenthal
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient Enrolled in a Phase III study with QUTENZA® in Post-Surgical Neuropathic Pain
Details : The Phase III study investigates the efficacy, safety, and tolerability of QUTENZA (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) to support an extension of the U.S. label.
Product Name : Qutenza
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
October 08, 2021
Details : Undisclosed
Product Name : Qutenza
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
July 19, 2021